Steroid Receptor Coactivator-3 Promotes Bladder Cancer Through Upregulation of CXCR4 |
Zhang, Yu
(Department of Urology, Shanghai Changning Center Hospital)
Wang, Ji-Hong (Department of Urology, Shanghai Jiao Tong University Affiliated 6th People's Hospital) Liu, Bin (Shanghai Institute of Materia Medica Chinese Academy of Sciences) Qu, Ping-Bao (Department of Urology, Shanghai Changning Center Hospital) |
1 | Lydon JP, O'Malley BW (2011). Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis. Endocrinology, 152, 19-25. DOI ScienceOn |
2 | Ma G, Ren Y, Wang K, He J (2011). SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci, 7, 664-72. |
3 | McBryan J, Theissen SM, Byrne C, et al (2012). Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res, 72, 548-59. DOI ScienceOn |
4 | Moi LL, Flågeng MH, Gjerde J, et al (2012). Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer, 15, 12:247. |
5 | Mussi P, Yu C, O'Malley BW, Xu J (2006). Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol, 20, 3105-19. DOI ScienceOn |
6 | Nishizawa K, Nishiyama H, Oishi S, et al (2010). Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. Int J Cancer, 127, 1180-7. |
7 | Palmieri C, Gojis O, Rudraraju B, et al (2013). Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br J Cancer, 108, 2039-44. DOI ScienceOn |
8 | Parkin DM, Pisani P, Ferlay J (2008). Global cancer statistics. CA Cancer J Clin, 49, 33-64. |
9 | Qin L, Liu Z, Chen H, Xu J (2009). The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res, 69, 3819-27. DOI ScienceOn |
10 | Retz MM, Sidhu SS, Blaveri E, et al (2005). CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer, 114, 182-9. DOI ScienceOn |
11 | Shen HB, Gu ZQ, Jian K, Qi J (2013). CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer. Tumour Biol, 34, 1839-45. DOI ScienceOn |
12 | Walsh CA, Qin L, Tien JC, Young LS, Xu J (2012). The function of steroid receptor coactivator-1 in normal tissues and cancer. Int J Biol Sci, 8, 470-85. DOI |
13 | Wang H, Yang D, Wang K, Wang J (2011). Expression and potential role of chemokine receptor CXCR4 in human bladder carcinoma cell lines with different metastatic ability. Mol Med Rep, 4, 525-8. |
14 | Wu RC, Feng Q, Lonard DM, O'Malley BW (2007). SRC-3 coactivator functional lifetime is regulated by a phosphodependent ubiquitin time clock. Cell, 129,1125-40. DOI ScienceOn |
15 | Xu J, Wu RC, O'Malley BW (2009). Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer, 9, 615-30. DOI ScienceOn |
16 | Yates TJ, Knapp J, Gosalbez M, et al (2013). C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer, 119, 61-71. DOI ScienceOn |
17 | Yi P, Feng Q, Amazit L, et al (2008). Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell, 29, 465-76. DOI ScienceOn |
18 | Yi P, Xia W, Wu RC, Lonard DM, Hung MC, et al (2013). SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev, 27, 274-87. DOI ScienceOn |
19 | York B, O'Malley BW (2010). Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem, 285, 38743-50. DOI |
20 | Cai D, Shames DS, Raso MG, et al (2010). Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res, 70, 6477-85. DOI ScienceOn |
21 | Coste A, Louet JF, Lagouge M, et al (2008). The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}. Proc Natl Acad Sci U S A, 105, 17187-92. DOI ScienceOn |
22 | Eisenhardt A, Frey U, Tack M, et al (2005). Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol, 47, 111-7. DOI ScienceOn |
23 | Geng C, He B, Xu L, et al (2013). Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A, 110, 6997-7002. DOI ScienceOn |
24 | Gojis O, Rudraraju B, Gudi M, et al (2010). The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol, 7, 83-9. DOI ScienceOn |
25 | Kuang SQ, Liao L, Zhang H, et al (2004). AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res, 64, 1875-85. DOI ScienceOn |
26 | Kucukgergin C, Isman FK, Dasdemir S, et al (2012). The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene, 511, 7-11. DOI ScienceOn |
27 | Lanz RB, Bulynko Y, Malovannaya A, et al (2010). Global characterization of transcriptional impact of the SRC-3 coregulator. Mol Endocrinol, 24, 859-72. DOI ScienceOn |
28 | Lonard DM, O'Malley BW (2012). Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol, 8, 598-604. DOI ScienceOn |
29 | Long W, Foulds CE, Qin J, et al (2012).ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest, 122, 1869-80. DOI ScienceOn |